Patents Assigned to Pneumagen Limited
  • Adjuvants
    Patent number: 11406704
    Abstract: The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 9, 2022
    Assignee: PNEUMAGEN LIMITED
    Inventors: Helen Connaris, Garry Taylor, Richard E. Randall
  • Treatment and/or prevention of sepsis
    Patent number: 10953078
    Abstract: The disclosure provides molecules with an affinity for (or an ability to bind to), sialic acid, for use in compositions, medicaments and methods for the treatment of sepsis, its symptoms and sepsis associated pathologies and immune responses.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: March 23, 2021
    Assignee: Pneumagen Limited
    Inventors: Helen Connaris, Garry Taylor, Hasan Yesilkaya, Peter Andrew